Recent Press Releases

Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options

Impax To Acquire Tower Holdings, Inc. And Lineage Therapeutics Inc.

-- Acquisitions includes operating subsidiaries CorePharma, LLC and Amedra Pharmaceuticals LLC -- -- Provides Portfolio of Growing, High-Margin, Complex Generic and Branded Products -- -- Enhances...

FDA Grants Priority Review for Genentech's Lucentis in Diabetic Retinopathy

FDA Grants Priority Review for Genentech's Lucentis in Diabetic Retinopathy South San Francisco, Calif. -- October 8, 2014 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),...

Allergan Provides Update on Earnings Per Share and Sales Expectations

IRVINE, Calif., Oct 09, 2014 (BUSINESS WIRE) -- Allergan, Inc. AGN, +0.26% today provided the following updates on earnings per share (EPS) and sales expectations based on current information....

Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S.

Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S. PRINCETON, N.J., Oct 08, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY, +0.41% has successfully resolved all outstanding...

Hospira Issues a Voluntary Nationwide Recall of One Lot of Vancomycin Hydrochloride for Injection USP, Equivalent to 1 G Vancomycin (Sterile Powder) Due to Uncontrolled Storage During Transit

Hospira Issues a Voluntary Nationwide Recall of One Lot of Vancomycin Hydrochloride for Injection USP, Equivalent to 1 G Vancomycin (Sterile Powder) Due to Uncontrolled Storage During Transit Contact...

Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting

Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)--Oct. 9, 2014-- Ironwood...

Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion

Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion - Auxilium Shareholders to Receive $33.25 Per Share - Combination Designed to Create Leading...

Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets

Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets Comprehensive clinical...

Changes to the Novartis Executive Committee after expected completion of portfolio transactions

Changes to the Novartis Executive Committee after expected completion of portfolio transactions Three members of the Executive Committee of Novartis to leave company, following completion of...

EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)

EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) EYLEA Now Approved for Wet Age-related Macular Degeneration (AMD), Diabetic Macular...

Health Care Providers and Services Stocks under Review - Community Health Systems, Tenet Healthcare, UnitedHealth, Molina Healthcare, and Cigna

Editor Note: For more information about this release, please scroll to bottom.

LONDON, October 6, 2014

Sucampo Announces Departure of Chief Financial Officer

Sucampo Announces Departure of Chief Financial Officer BETHESDA, Md., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today...

Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas

- Affirms its long-term commitment to being a world-leader in Central Nervous System and Respiratory - - Maintains its current commercial presence but stops Research & Development in other...

Actavis to Acquire Durata Therapeutics, Inc.

Actavis to Acquire Durata Therapeutics, Inc. Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings Enhances Actavis' Long-term Growth Profile...

Information on suspected side effects of nationally authorised medicines now available through a single website

Information on suspected side effects of nationally authorised medicines now available through a single website EMA encourages patients to report suspected side effects As of today, European citizens...

Merck Announces Proposed Public Debt Offering

Merck Announces Proposed Public Debt Offering WHITEHOUSE STATION, N.J., Oct 06, 2014 (BUSINESS WIRE) -- Merck & Co., Inc. (the "Company") MRK, +1.78% known as MSD outside the United States and...

Mylan Launches Generic Combivir(R)

Mylan Launches Generic Combivir(R) Product strengthens growing antiretroviral franchise in the U.S. PITTSBURGH, Oct. 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch...